Clinical Trials Logo

Healthy Volunteers clinical trials

View clinical trials related to Healthy Volunteers.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT06009237 Terminated - Healthy Volunteers Clinical Trials

A Study to Assess Pharmacokinetics, Safety, and Tolerability of ABBV-903 in Healthy Japanese and Han Chinese Participants

Start date: August 23, 2023
Phase: Phase 1
Study type: Interventional

The objective of this study is to assess the pharmacokinetics (PK), safety, and tolerability of ABBV-903 or placebo in healthy adult Japanese and Han Chinese subjects.

NCT ID: NCT05499780 Terminated - Healthy Volunteers Clinical Trials

Study on Performance and Safety of Sentinox in the Prevention of Acute Respiratory Infections (ARI)

Start date: November 7, 2022
Phase: N/A
Study type: Interventional

This is a post market, single-center, randomized, controlled, clinical study to assessTo evaluate the performance of self-administered Sentinox intranasal spray in preventing ARI caused by at least one respiratory virus

NCT ID: NCT05475821 Terminated - Healthy Volunteers Clinical Trials

Study to Assess Adverse Events and How Oral ABBV-990 Moves Through the Body of Adult Healthy Participants

Start date: July 25, 2022
Phase: Phase 1
Study type: Interventional

This study will assess how safe ABBV-990 is and how ABBV-990 moves through the body of adult healthy participants. Adverse Events will be assessed. ABBV-990 is an investigational drug being developed for the treatment of SARS-CoV-2 infections. Participants are randomly assigned to one of the 5 treatment groups. Each group receives different treatment. There is 1 in 4 chance that participants are assigned to placebo. Approximately 40 adult healthy volunteers will be enrolled in a single site in the United States. Participants will receive oral tablet of ABBV-990 or matching placebo on Day 1 and followed for approximately 30 days. Participants will be confined for 5 days. Adverse Events and blood tests will be performed.

NCT ID: NCT05367661 Terminated - Healthy Volunteers Clinical Trials

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CHK-336 in Healthy Volunteers

Start date: April 8, 2022
Phase: Phase 1
Study type: Interventional

This study is designed to assess the safety, tolerability, pharmacokinetics and pharmacodynamic effects of an investigational drug (CHK-336) when administered to healthy volunteers.

NCT ID: NCT05363839 Terminated - Healthy Volunteers Clinical Trials

To Assess the Safety, Tolerability and Pharmacokinetics of ACH-000029 in Healthy Subjects

Start date: May 6, 2022
Phase: Phase 1
Study type: Interventional

Randomized single ascending dose placebo controlled treatment of ACH-000029 administered orally via capsule in healthy volunteers.

NCT ID: NCT05330286 Terminated - Healthy Volunteers Clinical Trials

Study to Compare the Pharmacokinetics, Safety and Tolerability of the Pediatric and Adult Branaplam Formulation in Healthy Adults and the Effect of Food on the Latter.

Start date: April 13, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase 1 study designed to assess the relative bioavailability (BA), safety and tolerability and PK of the pediatric and adult formulations of branaplam.

NCT ID: NCT05307276 Terminated - Healthy Volunteers Clinical Trials

Limitation of the Ventilatory Response to Exercise in the Master Athlete

LAHMESS
Start date: April 1, 2022
Phase: N/A
Study type: Interventional

It is generally accepted that the ventilatory system is not a limiting factor in physical exercise in terms of performance or exercise tolerance in healthy subjects. The ventilatory system would be oversized in relation to the stresses it has to cope with, even during maximum intensity exercise. However, some highly trained endurance athletes may be exceptions to this rule. A limitation of the expiratory flow is indeed sometimes found in these athletes, whose maximum values of ventilation can confront the mechanical limits of their ventilatory system. This phenomenon could be accentuated in elderly athletes (known as "master athletes") under the effect of structural and functional pulmonary alterations that accompany aging. Our hypothesis : What is the prevalence of exercise expiratory flow limitation in the master athlete and does it cause a decrease in physical performance via an acceleration of locomotor muscle fatigue?

NCT ID: NCT05303909 Terminated - Healthy Volunteers Clinical Trials

The Immunostimulatory Effects of Gentamicin

Start date: May 11, 2022
Phase: Phase 2
Study type: Interventional

Gentamicin is one of the few aminoglycoside antibiotics which are approved for parenteral use in Singapore. As with other aminoglycosides, gentamicin is primarily bactericidal against Gram-negative organisms. It is well known that viral infection increases susceptibility to bacterial infection; increased rates of Gram-negative bacterial sepsis due to gastrointestinal tract bacterial translocation have been reported in Ebola and dengue patients. Gentamicin use in viral infection could thus improve clinical outcome by inhibiting both viral and opportunistic Gram-negative bacterial infection. Parenteral aminoglycosides do not cause perturbations or dysbiosis within the human gut microbiome. This is of importance as dysbiosis would not only increase the risk of antibiotic-resistant bacteria selection within the intestinal tract, it could also lead to negative downstream effects on the host response to infection by altering activation states of both innate and adaptive immunity. Thus, parenteral gentamicin may offer a unique approach to preventing both viral and downstream secondary Gram-negative bacterial infection, while at the same time minimizing the potential development of antibiotic resistance. The overarching goal of this study is to demonstrate that parenteral aminoglycosides exert broad-spectrum antiviral effects against RNA viruses in humans through their immunostimulatory properties. Using the live attenuated yellow fever (YF17D; stamaril) vaccine as an experimental viral infection model, a placebo controlled clinical trial will be carried out to demonstrate the efficacy of parenteral gentamicin in preventing viremia.

NCT ID: NCT05184218 Terminated - COVID-19 Clinical Trials

Evaluation of IGM-6268 in Healthy Adults and Patients With Mild to Moderate COVID-19

Start date: January 20, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase 1, multi-center, randomized, double-blinded, placebo-controlled study to assess the safety, tolerability, and pharmacokinetics (PK) of IGM-6268 administered intranasally and intraorally in healthy volunteers and in outpatients with mild-moderate COVID-19. IGM-6268 or placebo will be administered by intranasal + intraoral spray using a Teleflex Mucosal Atomization Device Nasalâ„¢ Intranasal Mucosal Atomization Device once, or once or twice each day for 5 days.

NCT ID: NCT05177029 Terminated - Healthy Volunteers Clinical Trials

Safety and Tolerability Study of Lu AG06466 in Healthy Young Japanese and Caucasian Participants

Start date: November 26, 2021
Phase: Phase 1
Study type: Interventional

The main goal of this study is to evaluate the effect of Lu AG06466 on the body and what the body does to Lu AG06466 after single and multiple doses to healthy Japanese and Caucasian participants.